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Abstract
Background: Symptoms and prognosis of patients with rheumatoid arthritis (RA) have improved with more
intensive therapy, including the biological disease-modifying anti-rheumatic drugs (bDMARDs). Real life data
concerning how comorbidities are distributed among patients treated or not treated with bDMARDs are scarce. Our
objective was to investigate differences in comorbidity and health care consumption in RA patients, with and
without bDMARDs.
Methods: This cross-sectional study was performed in the Southwestern part of Sweden. Patients, aged ≥ 18 years
and diagnosed with RA in secondary health care during 2009–2010, were identified in the regional health care
database. Aggregated data of comorbidity and health care consumption were retrieved between 2006 and 2010.
RA patients treated with bDMARDs on 31st December 2010 were identified in the Swedish Rheumatology Quality
Register (SRQ), which includes the biologics register Anti-Rheumatic Therapy in Sweden (ARTIS). Descriptive,
comparative, univariate and multiple logistic regression analyses were used to identify factors associated with
bDMARDs.
Results: Seven thousand seven hundred and twelve (7712) RA patients were identified (age 64.8 ± 14.9 years,
women 74.3%), of whom 1137 (14.7%) were treated with bDMARDs. Overall, the most common comorbidities
were infections (69.2%), hypertension (41.1%), chronic respiratory disease (15.3%), ischemic heart disease (14.0%)
and malignancy (13.7%). Patients without bDMARDs were older and had more comorbidity. In the multiple
logistic regression analysis, older age, cerebrovascular and chronic respiratory disease, heart failure, depression
and malignancy were all associated with no present bDMARDs. Infections were associated with bDMARDs.
Patients treated with bDMARDs consumed more secondary outpatient care but less visits in primary health care
compared to patients without bDMARDs.
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Conclusions: Patients treated with bDMARDs versus no bDMARDs were younger and had significantly lower
period prevalence for most common comorbidities, with the exception of infections. Differences in
comorbidities between RA patients with or without bDMARDs should be taken into consideration when
evaluating effectiveness and safety of bDMARDs in ordinary care.
Keywords: Rheumatoid arthritis, Comorbidity, Health care consumption, Biological therapy, bDMARDs, DMARDs,
Biologic agents
Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease, affects more women than men and has a peak age of
onset at the fifth to sixth decade of life [1]. Symptoms and
prognosis of RA patients have dramatically improved over
the last decades with more intensive therapy, including the
introduction of the TNF inhibitors and other biological
disease-modifying anti-rheumatic drugs (bDMARDs), such
as anakinra (interleukin-1 receptor inhibitor), rituximab
(monoclonal antibody against CD20 on B-cells), abatacept
(targeting T-cells activation) and tocilizumab (interleukin-6
receptor inhibitor) [2, 3]. The use of bDMARDs is steadily
increasing and bDMARDs are used in more early phases of
the disease [4].
It is well known that RA is associated with both higher
morbidity and mortality [5–10]. Several studies have shown
an increased risk of cardiovascular disease (CVD) [11–15],
which cannot fully be explained by traditional risk factors
[16, 17]. Systemic inflammation is considered to contribute
to the increased risk through accelerating the atheroscler-
otic process [18–20]. Studies have indicated that treatment
reducing the systemic inflammation, such as TNF inhibi-
tors, may reduce the cardiovascular risk [5, 21, 22]. How-
ever, observational studies like these are all likely to have
some residual confounding by indication despite different
attempts to overcome this. Such bias is, for example, likely
for comorbidity that constitutes an absolute or relative
contraindication for initiating bDMARDs therapy, i.e. heart
failure, malignant disease and severe infections. There may
also be other comorbidities and factors that clinicians may
take into account before initiating therapy with bDMARDs.
In addition, bDMARDs may themselves result in an in-
creased risk of opportunistic as well as other infections.
In the light of this background, the primary aim of this
study was to investigate the use of bDMARDs in pa-
tients with RA in the Southwestern part of Sweden and
to see whether demographics (age, sex), comorbidities
and health care consumption differed between patients
treated with or without bDMARDs.
Methods
Setting
This is a cross-sectional population-based analysis inves-
tigating RA patients treated with or without bDMARDs
on 31st December 2010. We have used the Swedish bio-
logics register Anti-Rheumatic Therapy in Sweden
(ARTIS) and five years of aggregated data from the re-
gional health care database, Vega. The study was per-
formed in the Region Västra Götaland, which is located
in the Southwest of Sweden. On 31st December 2010,
the region had 1,259,004 residents ≥ 18 years of age, repre-
senting 16.8% of the total Swedish population ≥ 18 years
of age [23]. There are five hospitals with rheumatology
clinics in the region, including Sahlgrenska University
Hospital in Gothenburg. There is universal access to pub-
licly funded health care for all Swedish residents. Practic-
ally all RA patients in Sweden are diagnosed and treated
at a specialist rheumatology clinic. According to a previ-
ous study, the RA patients have their first appointment
within a median time of three to four weeks after referral
to the rheumatology clinic [24]. RA patients treated with
bDMARDs are registered in the Swedish Rheumatology
Quality register (SRQ), which contains the ARTIS. The
national coverage of RA patients treated with bDMARDs
in the ARTIS has in a recent report been estimated to 95%
for the period 2008–2010 [25].
The regional health care data base, Vega, is an
administrative health care register in the Region Västra
Götaland and contains diagnoses registered within
medical records in this region as well as demographics
(sex, age, place of residence). Vega captures data from
inpatient and outpatient care, both primary and second-
ary care, within public health care as well as private set-
tings. Details are given concerning care providers,
primary and secondary diagnoses according to
International Classification of Diseases version 10 (ICD-10),
and dates of physician visit, admission and discharge.
According to a Swedish classification, held by the National
Board of Health and Welfare, the data base also includes
surgical and therapeutic procedure codes.
Patients
Patients treated with bDMARDs
We identified all patients with RA or inflammatory poly-
arthritis, aged ≥ 18 years and present treatment with
bDMARDs on 31st December 2010 according to data
from ARTIS. With regard to the rheumatic disease and
treatment with bDMARDs, the data from ARTIS were
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validated systematically against the medical records. Pa-
tients without RA diagnosis and/or without present
treatment with bDMARDs in the medical records were
excluded. Treatment with rituximab was considered as
present if the therapy was given less than two years
before 31st December 2010. Disease- and treatment-
specific data was extracted from ARTIS; disease
duration, presence of anti-citrullinated protein antibody
(ACPA) and rheumatoid factor (RF), erosive disease,
details of present bDMARDs, the number of previous
bDMARDs, concomitant conventional synthetic disease-
modifying anti-rheumatic drugs (csDMARDs), glucocor-
ticosteroids, erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), Disease Activity Score of 28
joints based on ESR and CRP (DAS28 and DAS28CRP
respectively) [26] and Health Assessment Questionnaire
disability index (HAQ-DI) [27]. The extracted data, such
as ACPA, RF, erosive disease and treatment-specific data,
were quality-controlled against medical records. The in-
formation was corrected when indicated. No imputa-
tions of remaining missing data were performed.
The patients identified in ARTIS were linked to Vega
using the unique personal identification number that all
Swedish residents have.
Patients without bDMARDs
To assemble a contemporary RA population without
present bDMARDs on 31st December 2010, we used
health care data from Vega. First, we identified all pa-
tients aged ≥ 18 years registered with a RA diagnosis in
any secondary health care at least once between 1st
January 2009 and 31st December 2010. ICD-10 codes
M05 and M06, except M061 (adult-onset Still’s disease)
and M064 (inflammatory polyarthritis), were used to de-
fine the RA diagnosis. Second, the RA patients found in
Vega and not simultaneously identified in the ARTIS ex-
traction as RA patients with present bDMARDs were
classified as “without bDMARDs”. No disease- and
treatment-specific data was available for RA patients
without bDMARDs.
For all identified RA patients (with and without
bDMARDs), health care data from January 2006 until
December 2010 were extracted. Patients residing outside
the Region Västra Götaland during the entire extraction
period in Vega were excluded.
Comorbidity and health care consumption
Comorbid conditions and health care consumption were
retrieved for the period 2006 to 2010. To capture both
common and less frequent comorbid conditions this five-
year period of historical register data was chosen. The
comorbid conditions identified were diabetes mellitus,
hypertension, ischemic heart disease, heart failure, valvular
disease, atrial fibrillation or flutter, cerebrovascular disease,
venous thromboembolic disease, chronic respiratory dis-
ease, chronic renal insufficiency, depression, malignancy,
infections, fractures at sites related to osteoporosis and
prosthetic surgery. Comorbid conditions were based on
ICD-10 codes registered at physician visits in primary and
secondary health care or as discharge diagnoses after
hospitalization. The used ICD-10 codes are described in de-
tail in the Additional file 1: Table S1. The percentage of
patients hospitalized at least once, as well as the number of
admissions and cumulative days of inpatient care at hospi-
tals were analysed. Hospitalization of one day with a regis-
tered therapeutic procedure code of intravenous therapy
could be solely due to the administration of intravenous
bDMARDs. These hospitalizations were therefore excluded.
The number of physician visits in primary and secondary
outpatient care were computed and presented separately.
Statistics
Descriptive statistics are presented as number (percent-
age), mean ± standard deviation (SD) or median (first,
third quartile). Comparisons between groups were
assessed by T-test or Mann-Whitney U test, chi-square
test or, when applicable, Fischer’s exact test. Univariate
and multiple logistic regression analyses with bDMARDs
(1) or not (0) as the dependent variable were used to
identify factors associated with usage of bDMARDs. Co-
morbid covariates were included in the models if they
differed significantly between the two groups in the
comparative analyses. In the univariate logistic regres-
sion analyses, each covariate was also adjusted for sex
and age. All tests were two-tailed and p < 0.05 was con-
sidered statistically significant. Statistical analyses were
performed by PASW Statistics 19 (SPSS Inc., IBM,
Chicago, USA) and SAS Version 9.3 (SAS Institute Inc.,
Cary, North Carolina, USA)
Results
In ARTIS, 1608 patients were first identified with
present bDMARDs, and 1137 of these patients met the
inclusion criteria after validation (Fig. 1). Three-hundred
and ninety patients had a RA diagnosis but no present
treatment with bDMARDs; 311 of these patients had a
history of previous bDMARDs and 79 patients were
planned to begin with a bDMARDs in 2011. These 390
RA patients were not included in the comparative ana-
lyses. In Vega, initially 6279 patients were identified
without bDMARDs, and 6185 of these met the inclusion
criteria (Fig. 1).
The characteristics of the RA patients treated with
bDMARDs are presented in Table 1. The mean age of
the patients was 58.9 years and 77.4% of them were
females. The patients had a longstanding, often RF posi-
tive and erosive, disease. TNF inhibitors represented
approximately 3/4 of the bDMARDs. DAS28 and HAQ
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were high before initiating the bDMARDs and had
decreased at follow-up.
Description and comparison of comorbid conditions and
health care consumption in RA patients with or without
bDMARDs
In Table 2, descriptive and comparative analyses of co-
morbid conditions and health care consumption during
the five-year period are displayed. A larger proportion of
males and significantly older age were noted for patients
without bDMARDs. The period prevalence of most of
the comorbid conditions was significantly higher in
patients without bDMARDs than in patients treated with
bDMARDs. On the contrary, infections were more com-
mon in patients treated with bDMARDS than in patients
without bDMARDs. The proportion of patients being
hospitalized as well as the number of admissions did not
differ significantly between those treated and not treated
with bDMARDs. Longer hospitalizations were noted for
patients without bDMARDs compared with patients
treated with bDMARDs. Outpatient physician visits in
secondary care were more frequent in patients treated
with bDMARDs in comparison with patients without
bDMARDs, while the opposite was noted for primary
health care visits.
Women and men were also analysed separately in order
to identify any sex-specific differences in comorbidity and
health care consumption within each sex (Table 3). The
pattern was similar, with older age and more comorbid
conditions in patients without bDMARDs in both the
male and female comparisons. Notably, in general men
had a higher period prevalence of comorbid conditions
than women, with the exception of depression, infections
and fractures.
In Table 4, the ten most common primary discharge
diagnoses are listed. The RA diagnosis was the main
reason for hospitalization in both RA patients with and
without bDMARDs, and especially in the group treated
with bDMARDs.
Comorbid conditions and health care consumption
associated with bDMARDs or not
In Table 5, the results of the age- and sex-adjusted uni-
variate and the multiple logistic regression analyses are
shown. The univariate analyses showed that cerebrovas-
cular and ischemic heart disease, heart failure, atrial
fibrillation, chronic respiratory disease, chronic renal in-
sufficiency, malignancy and depression all occurred
more frequently in those not treated with bDMARDs
than in those treated with bDMARDs, whereas the oc-
currence of infections were more frequent in those
treated with bDMARDs. Older age, but not sex, was as-
sociated with no present bDMARDs after the adjust-
ment. The significantly longer hospitalization in RA
patients without bDMARDs found in the comparative
analysis disappeared after the age- and sex-adjustment.
Fig. 1 Flow chart of the inclusion and exclusion process. ARTIS = Anti-Rheumatic Therapy in Sweden; the Swedish biologic register. Vega = the
regional health care data base. RA = rheumatoid arthritis. bDMARDs = biologic disease-modifying anti-rheumatic drugs. * M061 and M064
not included
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In the multivariable model, cerebrovascular and
chronic respiratory disease, heart failure, malignancy, de-
pression and older age were associated with no present
bDMARDs, while infections were associated with
bDMARDs.
Discussion
In this register-based study of RA, which covers 1/6 of
the Swedish adult population, we found a significantly
higher frequency of comorbid conditions in RA patients
not presently treated with bDMARDs compared to RA
patients treated with bDMARDs, even after adjusting for
the older age in RA patients without bDMARDs. RA
patients treated with bDMARDs consumed more
secondary health care, while the opposite were noted for
RA patients without bDMARDS in primary health care.
Our main objective was to investigate differences of co-
morbid conditions and health care consumption in RA pa-
tients with or without bDMARDs. The design of this study
did not allow us to address the causes of such differences.
Several factors may thus have influenced the results of this
cross-sectional analysis with five years of aggregated histor-
ical register data. Cerebrovascular and chronic respiratory
disease, heart failure, depression, malignancy and older age
were all associated with no present bDMARDs in this
study. Confounding by indication due to absolute or rela-
tive contraindications for initiating bDMARDs therapy will
automatically lead to lower frequency of malignancies and
heart failure in the RA group treated with bDMARDs. Also,
the older age and higher period prevalence of other comor-
bid conditions may suggest an increased fragility, which
may have lead the treating physicians to avoid bDMARDs
in these patients. This is in accordance with some previous
studies that have demonstrated a lower use of bDMARDs
in the elderly and that RA patients with less comorbidity
were more likely to be treated with bDMARDs [28–32]. In-
fections were associated with bDMARDs in our study. This
is in concordance with previous studies that have demon-
strated an elevated risk of infections in patients with
bDMARDs [7, 33]. In addition, part of the explanation may
be that patients with bDMARDs in a higher degree are ad-
vised to seek health care in case of infectious symptoms
and that severe RA is a risk factor for infections [34].
Studies specifically investigating the occurrence of co-
morbidities in the whole RA population, and not only in
subgroups, are relatively uncommon. The differences in
selection of patients, sex- and age-distribution, and col-
lection of comorbidity data make it difficult to compare
studies. A recent study by Dougados et al. reported a
great variability of comorbidities in RA between coun-
tries, where this variability may partly be associated with
the methods used to capture the information [35]. This
study included RA patients from 17 different countries.
The patients were younger than in our study and 39%
had been exposed to bDMARDs. Compared to our
results, Dougados et al. found similar prevalence of myo-
cardial infarction and hypertension, but lower prevalence
of malignancies and chronic obstructive pulmonary dis-
ease [35]. Likewise, even if not directly comparable
due to different study designs, our findings concerning
prevalence levels of the comorbid conditions are also
in the same range as in other studies where preva-
lence of comorbidities have been reported in RA
patients [36–39].
In the comparative analysis, we found a higher propor-
tion of female RA patients with bDMARDs. The same
result has been shown in other studies [39, 40]. How-
ever, in the multiple logistic regression analysis, we did
Table 1 Demographics and disease-characteristics of the 1137
RA patients treated with bDMARDs
Demographics and disease-characteristics
Women 880 (77.4)
Age, years 58.9 ± 12.3
Disease duration, years 16.2 ± 11.0
RF positive (n = 1132) 981 (86.7)
ACPA positive (n = 360) 297 (82.5)
Erosive disease (n = 1130) 980 (86.7)
DAS28, before start on present bDMARDs (n = 808) 5.16 ± 1.23
DAS28, last follow-up on present bDMARDs (n = 814) 3.02 ± 1.26
HAQ score, before start on present bDMARDs (n = 854) 1.29 ± 0.64
HAQ score, last follow-up on present bDMARDs (n = 839) 0.93 ± 0.65
Present bDMARDs







Concomitant csDMARDs and glucocorticosteroids at
last follow-up (n = 983)
Any csDMARDs 826 (84.0)
Methotrexate 749 (76.2)
Glucocorticosteroids (prednisolone) 284 (28.9)





Data are expressed as mean ± SD or number (%). Data are presented for 1137
patients, but when data are missing, the numbers of patients are given. RF =
rheumatoid factor, ACPA = anti-citrullinated protein antibody, DAS28 = disease
activity score of 28 joints, HAQ = health assessment questionnaire, bDMARDs
= biological disease-modifying anti-rheumatic drugs, csDMARDs = conventional
synthetic disease-modifying anti-rheumatic drugs
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not find sex to be associated with bDMARDs. This was
probably a result of the higher burden of comorbidity
that was found in male patients.
The disease characteristics in RA patients treated with
bDMARDs were as expected in relation to the present
recommendations regarding the initiation of bDMARDs.
Furthermore, the health care consumption, in particular
in secondary care, was high in the RA population treated
with bDMARDs, and hospitalization often linked to the
RA diagnosis per se.







P-value (bio vs no bio)
Women, n (%) 5727 (74.3) 880 (77.4) 4559 (73.7) 0.009
Age, years 64.8 ± 14.9 58.9 ± 12.3 66.2 ± 15.1 <0.001
Comorbid conditions, n (%)
Diabetes mellitus 860 (11.2) 93 (8.2) 715 (11.6) 0.001
Hypertension 3169 (41.1) 359 (31.6) 2662 (43.0) <0.001
Ischemic heart disease 1077 (14.0) 92 (8.1) 947 (15.3) <0.001
Unstable angina
Myocardial infarction













Heart failure 715 (9.3) 33 (2.9) 656 (10.6) <0.001
Valvular disease 250 (3.2) 23 (2.0) 218 (3.5) 0.009
Atrial fibrillation or flutter 722 (9.4) 50 (4.4) 645 (10.4) <0.001




































Chronic respiratory disease 1178 (15.3) 130 (11.4) 984 (15.9) <0.001















Chronic renal insufficiency 162 (2.1) 8 (0.7) 143 (2.3) <0.001
Depression 888 (11.5) 104 (9.1) 738 (11.9) 0.007
Malignancy 1059 (13.7) 87 (7.7) 921 (14.9) <0.001
























Patients hospitalizeda, n (%) 4001 (51.9) 571 (50.2) 3201 (51.8) 0.341
Number of inpatient admissionsa









Outpatient visits, secondary care 13 (7, 21) 21 (14, 34) 11 (7, 18) <0.001
Outpatient visits, primary care 8 (4, 14) 7 (3, 11) 9 (5, 15) <0.001
Data are expressed as number (%), mean ± SD or median (first, third quartile). Numbers of admissions, cumulative days at hospital and outpatient visits are
calculated on patients who have been hospitalized or have been in outpatient care, respectively, and not on all patients. TIA = transient ischemic attack, COPD =
chronic obstructive pulmonary disease
aHospitalizations of one day and connected to an intravenous treatment were not included
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There are several strengths of this present study. First,
the large number of RA patients, which comprised 1/6
of the total Swedish adult population. The register-based
study design has also assured that certain categories of
patients, for example older patients, were not excluded.
Second, the construction of our regional health care data
base, including both inpatient care as well as primary
and secondary outpatient care, enabled us to catch those
comorbid conditions that do not necessarily need
hospitalization or secondary outpatient care, such as
hypertension, diabetes, chronic respiratory disease and
depression. Third, our national biologic register ARTIS
has an almost complete coverage of RA patients treated
with bDMARDs [25].
There are limitations of the present study that must
also be acknowledged. First, we cannot exclude misclas-
sifications of diagnoses in the register and this is also the
case for the RA diagnosis in the patients without
bDMARDs. Though, our data gives a calculated RA
period prevalence of 0.61% in our region, which is in ac-
cordance with previously published data from Sweden
[31, 40]. The ICD-codes in Vega have not been validated
previously. The secondary health care (secondary out-
patient care and inpatient care) also report to the Swed-
ish National Patient Register. The inpatient part of this
register has been validated and the positive predictive
value was found to differ between diagnoses but was
generally high (85–95%) [41]. Second, RA patients only
followed in primary health care and RA patients with
physician visits less than every second year are not iden-
tified in our investigation. Third, the cross-sectional
study design makes it impossible to draw conclusions of
causality between comorbidities and health care con-
sumption with respect to treatment with bDMARDs or










Age, years 58.7 ± 12.4 65.6 ± 15.6 <0.001 59.7 ± 12.0 67.6 ± 13.5 <0.001
Comorbid conditions, n (%)
Diabetes mellitus 62 (7.0) 478 (10.5) 0.002 31 (12.1) 237 (14.6) 0.284
Hypertension 268 (30.5) 1932 (42.4) <0.001 91 (35.4) 730 (44.9) 0.004
Ischemic heart disease 48 (5.5) 591 (13.0) <0.001 44 (17.1) 356 (21.9) 0.082
Heart failure 21 (2.4) 416 (9.1) <0.001 12 (4.7) 240 (14.8) <0.001
Valvular disease 15 (1.7) 151 (3.3) 0.011 8 (3.1) 67 (4.1) 0.443
Atrial fibrillation or flutter 34 (3.9) 396 (8.7) <0.001 16 (6.2) 249 (15.3) <0.001
Cerebrovascular disease 30 (3.4) 392 (8.6) <0.001 15 (5.8) 182 (11.2) 0.009
Venous thromboembolic disease 41 (4.7) 260 (5.7) 0.215 6 (2.3) 103 (6.3) 0.011
Chronic respiratory disease 91 (10.3) 702 (15.4) <0.001 39 (15.2) 282 (17.3) 0.390
Chronic renal insufficiency 6 (0.7) 90 (2.0) 0.008 2 (0.8) 53 (3.3) 0.028
Depression 87 (9.9) 614 (13.5) 0.004 17 (6.6) 124 (7.6) 0.567
Malignancy 61 (6.9) 597 (13.1) <0.001 26 (10.1) 324 (19.9) <0.001
































Patients hospitalizeda, n (%) 449 (51.0) 2369 (52.0) 0.609 122 (47.5) 832 (51.2) 0.271
Number of inpatient admissionsa













Outpatient visits, secondary care 22 (15, 34) 11 (7, 18) <0.001 20 (12, 32) 11 (7, 18) <0.001
Outpatient visits, primary care 7 (3, 11) 9 (5, 15) <0.001 6 (3, 11) 8 (4, 13) <0.001
Data are expressed as number (%), mean ± SD or median (first, third quartile). Numbers of admissions, cumulative days at hospital or outpatient visits are
calculated on patients who have been hospitalized or have been in outpatient care, respectively, and not on all patients
aHospitalizations of one day and connected to an intravenous treatment were not included
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Table 4 The top ten primary discharge diagnoses in patients with and without bDMARDs 2006–2010
Primary discharge diagnoses in RA patients with bDMARDs (n = 2205) Primary discharge diagnoses in RA patients without bDMARDs (n = 13,206)
1 Rheumatoid arthritis 800 (36.3) Rheumatoid arthritis 1483 (11.2)
2 Ischemic heart disease 56 (2.5) Ischemic heart disease 626 (4.7)
3 Fractures 51 (2.3) Fractures 585 (4.4)
4 Osteoarthritis 42 (1.9) Pneumonia 469 (3.6)
5 Pneumonia 41 (1.9) Chest pain 349 (2.6)
6 Chest pain 41 (1.9) Atrial fibrillation 330 (2.5)
7 Atrial fibrillation 35 (1.6) Heart failure 312 (2.4)
8 Childbirth 34 (1.5) Osteoarthritis 297 (2.2)
9 Abdominal pain 31 (1.4) Stroke (hemorrhagic or ischemic) 247 (1.9)
10 Cholecystitis and/or gall stone 22 (1.0) Urinary tract infection 236 (1.8)
Stroke 21 (1.0) Abdominal pain 231 (1.7)
Urinary tract infection 17 (0.8) Childbirth 172 (1.3)
Heart failure 6 (0.3) Cholecystitis and/or gall stone 121 (0.9)
Data are expressed as number (%). N = number of hospitalizations 2006–2010 when hospitalizations of one day and connected to an intravenous treatment, were not
included. ICD-10 codes from the Z section are not included. In cursive, the corresponding number (%) is given in the other group if not already existing in the top ten
Table 5 Associations with bDMARDs (1) or no bDMARDs (0), univariate and multiple logistic regression analyses
Covariates Univariate analyses (sex- and age-adjusted) Multiple analysis
Odds ratio 95% confidence intervals P-value Odds ratio 95% confidence intervals P-value
Age (per 1 year) 0.97 0.97–0.97 <0.001 0.98 0.97–0.98 <0.001
Sex 0.88 0.76–1.03 0.103 0.94 0.81–1.10 0.450
Comorbid conditions
Diabetes 0.86 0.69–1.09 0.218 0.96 0.76–1.22 0.758
Hypertension 0.89 0.76–1.03 0.108 0.95 0.81–1.11 0.513
Ischemic heart disease 0.73 0.58–0.93 0.009 0.90 0.70–1.15 0.384
Atrial fibrillation or flutter 0.64 0.47–0.86 0.004 0.83 0.60–1.15 0.260
Heart failure 0.40 0.28–0.58 <0.001 0.47 0.32–0.69 <0.001
Valvular disease 0.82 0.53–1.27 0.375 1.11 0.70–1.75 0.657
Cerebrovascular disease 0.59 0.43–0.82 0.001 0.65 0.47–0.90 0.010
Venous thromboembolic disease 0.83 0.61–1.14 0.259 0.92 0.67–1.27 0.607
Chronic respiratory disease 0.80 0.66–0.98 0.031 0.82 0.67–0.998 0.048
Chronic renal insufficiency 0.43 0.21–0.89 0.022 0.53 0.25–1.09 0.084
Depression 0.72 0.58–0.90 0.004 0.74 0.59–0.92 0.008
Malignancy 0.66 0.52–0.84 0.001 0.66 0.52–0.84 0.001
Infections 1.39 1.21–1.61 <0.001 1.52 1.31–1.76 <0.001
Fractures 1.01 0.77–1.33 0.947 1.06 0.81–1.41 0.660
Health care consumption
Patients hospitalizeda 1.15 1.01–1.31 0.040
Number of inpatient admissionsa 1.03 1.00–1.07 0.042
Cumulative days at hospitala 0.997 0.99–1.00 0.101
Outpatient visits, secondary care 1.06 1.06–1.07 <0.001
Outpatient visits, primary care 0.97 0.96–0.98 <0.001
Analyses were performed with (multiple) logistic regression models and expressed as Odds ratios (with 95% confidence intervals and p-value). In the univariate
analyses, each covariate was adjusted for sex and age. Age and sex were adjusted for each other. In the multivariable analysis, all of the comorbid conditions
covariates in the table were included in the model
aHospitalizations of one day and connected to an intravenous treatment were not included
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not. Other limitations are the lack of information about
disease- and treatment-specific characteristics of RA pa-
tients without bDMARDs.
Conclusions
In this cross-sectional analysis with five years of aggre-
gated historical register data, we show a clear difference
between RA patients with and without bDMARDs con-
cerning age, comorbid pattern and health care consump-
tion. RA patients treated with bDMARDs were younger,
had less comorbid conditions, and consumed more sec-
ondary outpatient care but less primary outpatient care.
These differences in characteristics between RA patients
with or without bDMARDs have to be taken into con-
sideration when evaluating the effectiveness and safety
of bDMARDs in ordinary care.
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